1. Home
  2. ELUT vs INTS Comparison

ELUT vs INTS Comparison

Compare ELUT & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elutia Inc.

ELUT

Elutia Inc.

HOLD

Current Price

$0.59

Market Cap

23.3M

Sector

Health Care

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.38

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELUT
INTS
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3M
24.0M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
ELUT
INTS
Price
$0.59
$0.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$7.00
$4.33
AVG Volume (30 Days)
502.1K
3.2M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$21,746,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$0.50
$0.19
52 Week High
$3.99
$3.17

Technical Indicators

Market Signals
Indicator
ELUT
INTS
Relative Strength Index (RSI) 43.34 43.50
Support Level $0.52 $0.37
Resistance Level $0.59 $0.43
Average True Range (ATR) 0.06 0.05
MACD 0.00 -0.01
Stochastic Oscillator 39.34 9.65

Price Performance

Historical Comparison
ELUT
INTS

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: